医疗设备行业——2025 医药三季报分析电话会 20251104 摘要 医疗设备行业整体呈现恢复迹象，但毛利率因集采和设备更新招采影响 有所下滑。招投标活动持续恢复，前三季度中标金额同比增长 32%，CT 和磁共振增速尤为突出，均超过 70%。 海外业务成为增长引擎，前三季度增长 22%，北美、欧洲及亚太核心项 目进入集中落地阶段，订单向收入转化效率提升。迈瑞医学影像线国际 收入占比达 61%，联影海外业务增长 42%。 各细分领域表现分化，医学影像设备（联影、迈瑞、开立）、常规医疗 设备、家用医疗设备（受益于国补政策）及康复设备（伟思医疗 Q3 收 入增长 12%）均有亮点。 迈瑞医疗 Q3 业绩亮眼，预计 Q4 收入增幅将提升；开立医疗超声和内 镜产品中标金额显著增加；联影国内增长 24%，海外增长 42%；愉悦 医疗 Q3 主营业务稳健增长 10%。 未来，企业出海趋势将持续，宏观环境和地缘政治冲突带来挑战。招投 标复苏将在 Q4 兑现为收入。各公司积极布局高端产品线，如超声 8,090 平台、内镜 650 系列等，预计 2026 年放量。 Q&A 2025 年第三季度医疗设备板块的整体表现如何？ 20 ...

Investment Rating - The industry investment rating is maintained at "Outperform" [3][52]. Core Insights - In September 2025, the total bid amount for medical devices reached 15.534 billion yuan, showing a month-on-month increase of 18% but a year-on-year decrease of 3%. The total bid amount from January to September 2025 was 125.908 billion yuan, reflecting a year-on-year growth of 42% [4][9]. Summary by Sections Medical Device Procurement Overview - The total bid amount for medical devices in September 2025 was 15.534 billion yuan, with a month-on-month increase of 18% and a year-on-year decrease of 3%. The cumulative bid amount from January to September 2025 was 125.908 billion yuan, representing a year-on-year increase of 42% [4][9]. Domestic Brands - **United Imaging**: In September 2025, the total bid amount was 836 million yuan, a year-on-year increase of 23%. From January to September 2025, the total was 7.871 billion yuan, up 55% year-on-year [5][13]. - **Myray Medical**: The total bid amount in September 2025 was 999.2 million yuan, a year-on-year increase of 14% and a month-on-month increase of 18%. The cumulative amount from January to September was 6.898 billion yuan, reflecting a year-on-year growth of 43% [17][18]. - **Kaili Medical**: The total bid amount in September 2025 was 162 million yuan, a year-on-year increase of 65%. The cumulative amount from January to September was 1.067 billion yuan, up 94% year-on-year [25][26]. - **Wandong Medical**: The total bid amount in September 2025 was 130 million yuan, a year-on-year increase of 51%. The cumulative amount from January to September was 1.066 billion yuan, reflecting a year-on-year growth of 98% [33][34]. - **Shanwaishan**: The total bid amount in September 2025 was 66 million yuan, a year-on-year increase of 25%. The cumulative amount from January to September was 349 million yuan, up 134% year-on-year [29][30]. Imported Brands - **Philips**: The total bid amount in September 2025 was 980 million yuan, a year-on-year increase of 36%. The cumulative amount from January to September was 6.701 billion yuan, reflecting a year-on-year growth of 32% [36][37]. - **Siemens**: The total bid amount in September 2025 was 1.014 billion yuan, a year-on-year increase of 8%. The cumulative amount from January to September was 8.502 billion yuan, up 42% year-on-year [40][41]. - **GE Medical**: The total bid amount in September 2025 was 1.288 billion yuan, a year-on-year increase of 6%. The cumulative amount from January to September was 9.822 billion yuan, reflecting a year-on-year growth of 36% [44][45].

Core Points - WanDong Medical announced on October 31 that it has repurchased a total of 1,175,000 shares through centralized bidding, which represents 0.1671% of the company's total share capital [2] Summary by Category Company Actions - The company has engaged in a share repurchase program, acquiring 1,175,000 shares [2] - The repurchased shares account for 0.1671% of the total share capital [2] Market Impact - The announcement may influence investor sentiment and market perception regarding the company's financial health and commitment to shareholder value [2]

Group 1 - Company announced a share buyback of approximately 1.18 million shares, representing 0.1671% of total share capital, with a total expenditure of around 20 million yuan [1] - The highest and lowest prices for the repurchased shares were 17.99 yuan and 16.15 yuan per share, respectively [1] - As of the announcement, the company's market capitalization stands at 11.2 billion yuan [1] Group 2 - For the year 2024, the revenue composition of the company is projected to be 93.68% from medical device manufacturing and 6.32% from other businesses [1]

证券代码：600055 证券简称：万东医疗 编号：临 2025-048 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 0.3 亿元、自有资金 2.1 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 2025 年 10 月 13 日，公司以 8,000 万元自有资金购买了招商银行点金 受托方名称 产品 ...

证券代码：600055 证券简称：万东医疗 公告编号：临 2025-049 北京万东医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至 2025 年 11 月 1 日，公司通过集中竞价交易方式累计回购股份 1,175,000 股，已回购股份占公司总股本的比例为 0.1671 %，购买的最高价 为 17.99 元/股、最低价为 16.15 元/股，已支付的总金额为 19,996,245 元（不 含交易费用）。本次回购股份符合相关法律法规的规定和回购股份方案的要求。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自 律监管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况 择机做出回购决策并予以实施，同时根据回购股份事项进展情况及时履行信 息披露义务，敬请广大投资者注意投资风险。 关于股份回购进展的公告 重要内容提示： | 回购方案首次披露日 | 2025/8/23 | | | | | | --- | --- | --- | --- | --- | --- | ...

Group 1 - The company, Wandong Medical (600055.SH), announced a share buyback program, having repurchased a total of 1.175 million shares as of November 1, 2025 [1] - The repurchased shares account for 0.1671% of the company's total share capital [1] - The highest purchase price was 17.99 CNY per share, while the lowest was 16.15 CNY per share, with a total expenditure of 19.9962 million CNY (excluding transaction fees) [1]

Core Viewpoint - WanDong Medical's stock price has shown fluctuations, with a year-to-date increase of 6.75% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, WanDong Medical achieved a revenue of 1.189 billion yuan, reflecting a year-on-year growth of 8.73%. However, the net profit attributable to shareholders was a loss of 27.21 million yuan, a significant decrease of 123.51% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 769 million yuan, with 267 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,200, up by 1.23% from the previous period. The average number of circulating shares per person decreased by 1.22% to 25,882 shares [2]. - Among the top ten circulating shareholders, HuaBao ZhongZheng Medical ETF holds 11.92 million shares, a decrease of 2.10 million shares from the previous period. Conversely, Hong Kong Central Clearing Limited increased its holdings to 7.03 million shares, up by 253,640 shares [3]. Market Activity - On October 31, WanDong Medical's stock rose by 2.04%, reaching 15.98 yuan per share, with a trading volume of 56.88 million yuan and a turnover rate of 0.51%. The total market capitalization stands at 11.235 billion yuan [1]. - The stock has experienced a decline of 5.72% over the last five trading days, 9.56% over the last twenty days, and 8.53% over the last sixty days [1]. Business Overview - WanDong Medical, established on May 12, 1997, and listed on May 19, 1997, is primarily engaged in the research, manufacturing, sales of imaging medical devices, and imaging diagnostic services. The revenue composition includes 90.72% from medical device sales, 5.66% from medical services, and 3.62% from other sources [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with concepts such as smart healthcare and interconnected medical services [1].

Core Viewpoint - The company reported a decline in net profit for Q3 2025, despite a steady revenue growth in the first three quarters, indicating pressure on profitability due to increased expenses and price reductions from centralized procurement [1][2]. Group 1: Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.189 billion yuan, representing a year-on-year growth of 8.73%, but reported a net loss of 27 million yuan, a decline of 123.51% [1]. - In Q3 2025, the company generated a revenue of 345 million yuan, down 12.17% year-on-year, with a net loss of 79 million yuan, a significant drop of 353.32% [1]. - The gross margin decreased to 32.6%, down 5.1 percentage points, due to the impact of centralized procurement price reductions [1]. Group 2: Market Strategy and Growth - The company is focusing on high-end markets and county-level markets, with domestic revenue reaching 750 million yuan, a growth of 6%, despite a temporary decline in Q3 due to reduced private procurement demand [2]. - The company has established a K3 team to target tertiary public hospitals, contributing 12.4% to domestic revenue with a year-on-year growth of 25% [2]. - The company maintains a leading market share in various product segments, including over 30% in DR, over 20% in CT and MR, and 12% in DSA among domestic brands [2]. Group 3: International Expansion - The company reported international revenue of 180 million yuan, a growth of 50%, with significant increases in Europe (157%), Asia-Pacific (148%), and the Middle East and Africa (90%) [2]. - The company is enhancing its global service capabilities by establishing regional service centers and local offices, aiming for sustained high growth over the next three years [2]. Group 4: Profit Forecast - Revenue projections for 2025-2027 are 1.948 billion, 2.491 billion, and 3.363 billion yuan, with year-on-year growth rates of 27.77%, 27.89%, and 35.02% respectively [3]. - Expected net profits for the same period are 22 million, 76 million, and 111 million yuan, with growth rates of -86.30%, 251.71%, and 45.78% respectively [3].

Core Viewpoint - WanDong Medical is a leading domestic enterprise in the medical imaging field, focusing on imaging medical devices with significant potential for overseas business growth [1] Group 1: Business Performance - In Q3 2025, WanDong Medical achieved a revenue of 1.189 billion yuan, ranking 15th among 42 companies in the industry, significantly lower than the top player Mindray Medical's 25.834 billion yuan and second-place United Imaging's 8.859 billion yuan [2] - The main business composition includes medical device sales of 765 million yuan, accounting for 90.72%, and medical services and others at 47.788 million yuan, accounting for 5.66% [2] - The net profit for the period was -27.5465 million yuan, ranking 38th in the industry, far behind Mindray Medical's 7.814 billion yuan and second-place Yuyue Medical's 1.466 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, WanDong Medical's debt-to-asset ratio was 15.88%, up from 9.08% year-on-year, but still below the industry average of 27.21%, indicating strong debt repayment capability [3] - The gross profit margin for Q3 2025 was 32.62%, down from 38.33% year-on-year and lower than the industry average of 48.67%, suggesting a need for improvement in profitability [3] Group 3: Executive Compensation - The salary of President Song Jinsong was 1.9163 million yuan in 2024, an increase of 1.8125 million yuan compared to 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.23% to 27,200, with an average holding of 25,900 circulating A-shares, a decrease of 1.22% [5] Group 5: Market Outlook - CITIC Securities noted that WanDong Medical is expected to maintain a leading market share in DR and other advantageous categories due to new equipment update policies, with annual revenue growth projected to exceed 20% [6] - The company is forecasted to achieve revenues of 1.858 billion yuan, 2.325 billion yuan, and 2.972 billion yuan for 2025 to 2027, with respective year-on-year growth rates of 22%, 25%, and 28% [6]